更新于：2024-11-01

Ovarian Germ Cell Cancer

卵巢生殖细胞癌

更新于：2024-11-01

基本信息

别名

MOGCT、Malignant Germ Cell Neoplasm of Ovary、Malignant Germ Cell Neoplasm of the Ovary

+ [24]

简介

An invasive malignant neoplasm that arises from the ovary and originates from primordial germ cells. Representative examples include embryonal carcinoma, yolk sac tumor, dysgerminoma, and non-gestational choriocarcinoma.

关联

项与卵巢生殖细胞癌相关的药物

Nivolumab

纳武利尤单抗

靶点

PD-1

作用机制

PD-1抑制剂

在研机构

Ono Pharmaceutical Co., Ltd. [+21]

原研机构

Ono Pharmaceutical Co., Ltd. [+1]

在研适应症

皮肤肿瘤 [+459]

非在研适应症

异戊酸血症 [+83]

最高研发阶段批准上市

首次获批国家/地区

日本

首次获批日期2014-07-04

Cabozantinib (s)-Malate

苹果酸卡博替尼

靶点

AXL x RET x ROS1 x TYRO3 x Tie-2 x TrkB x VEGFR1 x VEGFR2 x VEGFR3 x c-Kit x c-Met

作用机制

AXL抑制剂 [+10]

在研机构

National Cancer Institute [+14]

原研机构

Exelixis, Inc.

在研适应症

甲状腺癌 [+190]

非在研适应症

晚期胆道癌 [+41]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2012-11-29

Ipilimumab

伊匹木单抗

靶点

CTLA4

作用机制

CTLA4抑制剂

在研机构

Bristol Myers Squibb Co. [+11]

原研机构

Bristol Myers Squibb Co.

在研适应症

不能切除的食管鳞状细胞癌 [+287]

非在研适应症

复发性急性淋巴细胞白血病 [+97]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2011-03-25

项与卵巢生殖细胞癌相关的临床试验

CTR20242917 / Recruiting临床1期

一项探索BGB-B2033单药治疗以及与替雷利珠单抗联合治疗在选定的晚期或转移性实体瘤受试者中的安全性、耐受性、药代动力学、药效学和初步抗肿瘤活性的1期研究（目前仅开展单药试验）

主要目的： 1.评估BGB-B2033在晚期或转移性HCC、产生AFP的GC、性腺外卵黄囊肿瘤、非无性细胞瘤或GPC3阳性鳞状NSCLC受试者中的安全性和耐受性 2.确定BGB-B2033的MTD或MAD和RP2D

开始日期2024-08-28

申办/合作机构

广州百济神州生物制药有限公司

NCT06329323 / Not yet recruitingN/AIIT

SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours

The goal of this observational case-control study is to learn about the circulating and tissue microRNA expression, imaging and radiomic profiles of malignant ovarian germ cell tumours (MOGCT) compared to patients with a benign OGCT and no ovarian pathology.
The main question[s] it aims to answer are:
To understand the circulating miRNA expression of malignant ovarian germ cell tumours (MOGCTs) compared to those with benign ovarian germ cell tumours (BOGCTs)
To understand the imaging profile of MOGCTs compared to that of BOGCTs
To establish the relationship between serum and plasma miRNA expression in response to treatment and relapse of disease
To discover if miRNA expression correlates with radiomic features of OGCTs on both ultrasound and MRI
To see if we can link the micro RNAs in tumour samples to those found in blood samples, and to find a plausible explanation for why these micro RNAs are raised (in terms of the tumour biology itself).aims
Participants will have serial blood tests at different time points in their care to assess how circulating miRNA levels are affected by treatment and/or remission and/or relapse. If they have surgery, a pathology sample will be taken from the main tumour specimen. Radiomic analysis will take place on existing ultrasound images of their mass.
Researchers will compare the circulating miRNA profile of patients with a benign ovarian germ cell tumour and no ovarian pathology to see where the differences lie. If a patient with a BOGCT requires surgery, a pathology sample will be taken from the main tumour specimen. Radiomic analysis will take place on existing ultrasound images of their benign mass.

开始日期2024-04-14

申办/合作机构

Imperial College London

NCT06276491 / Recruiting临床1期

A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb®541 in Advanced Solid Tumors

The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate effect of XmAb541 on tumor outcomes.

开始日期2024-04-04

申办/合作机构

Xencor, Inc.

100 项与卵巢生殖细胞癌相关的临床结果

登录后查看更多信息

100 项与卵巢生殖细胞癌相关的转化医学

登录后查看更多信息

0 项与卵巢生殖细胞癌相关的专利（医药）

登录后查看更多信息

800

项与卵巢生殖细胞癌相关的文献（医药）

2024-12-01·Gynecologic Oncology Reports

Treatment of recurrent ovarian germ cell tumours: Is there a role for immune checkpoint inhibitors?

Review

作者: Bernard, Laurence

Ovarian germ cell tumours predominantly affect young women and have an excellent prognosis. While most contemporary papers concentrate on reducing treatment morbidity and preserving fertility, some women still succumb to refractory or recurrent OGCTs. Despite the significant impact of immune checkpoint inhibitors (ICIs) on many tumors, no case of a chemo-resistant ovarian germ cell tumour successfully treated with immunotherapy has been reported. In testicular cancer, only a few cases of partial response or stable disease to ICIs have been described. PD-L1 expression does not predict response, but microsatellite instability status may serve as a potential biomarker. MSI testing should be performed on a recurrent tumour sample as MSI status may evolve during treatment.

2024-10-01·Case Reports in Women's Health

Elevated lactate dehydrogenase – A red herring in the diagnosis of a sclerosing stromal tumor: A case report

Article

作者: Pfaendler, Krista ; Gross, Alexander ; Flanagan, Melina ; Devlin, Kelly

Sclerosing stromal tumors are a rare type of ovarian tumor in the category of sex cord stromal tumors, which arise from the ovarian connective tissue. This report concerns a case of a sclerosing stromal tumor in a 19-year-old nulliparous woman who presented with the chief complaints of menstrual irregularities and dyspareunia. Preoperative imaging revealed a complex right adnexal mass with blood flow and without associated ascites. Tumor markers were all normal except lactate dehydrogenase, which was elevated. The elevated lactate dehydrogenase, in combination with patient age and menstrual irregularities, initially misdirected the clinicians toward suspicion for dysgerminoma or other malignant germ cell tumor of the ovary. Clinicians should beware of excluding the diagnosis of sex cord stromal tumor on the differential in a young person with an adnexal mass and elevated lactate dehydrogenase.

2024-09-23·Qatar Medical Journal

Pediatric puzzle: Large ovarian dermoid cyst and markedly elevated CA 19-9 in an 8-year-old

Article

作者: Abdelmoaty, Muhamed Ahmed ; Taha, Wael Soliman

BackgroundMature cystic teratomas, also known as dermoid cysts, are the most prevalent form of ovarian germ cell tumors. While they typically manifest in women of reproductive age, they can also occur in pediatric patients. These tumors are generally benign and comprise a diverse array of tissue types. However, large lesions, particularly those exceeding 10 cm in diameter, are infrequent and can present diagnostic and therapeutic challenges. Notably, elevated tumor markers, such as cancer antigen 19-9 (CA 19-9), are not commonly associated with mature cystic teratomas, rendering this case particularly unusual.Case presentationThe clinical case involved an 8-year-old female patient who presented with an exceptionally large ovarian teratoma, measuring 13 × 12 cm. While the prepubertal presentation of such tumors is not uncommon, the remarkable size of the lesion was an extraordinary occurrence. Preoperative evaluation revealed markedly elevated levels of CA 19-9, a tumor marker, at 297 U/mL-an atypical finding for mature cystic teratomas. Imaging studies identified a complex cystic adnexal mass, indicative of a teratoma. Consequently, a laparotomy was performed, revealing an intact, benign lesion that was successfully resected via cystectomy, with preservation of the ovary. Histopathological examination confirmed the diagnosis of a mature cystic teratoma, without any evidence of malignant transformation. Notably, following the surgical intervention, the elevated CA 19-9 levels normalized, suggesting a potential association between the teratoma and the abnormal tumor marker levels.DiscussionThis report delineates the surgical management and clinical course of an exceptionally large ovarian teratoma in a pediatric patient with abnormal preoperative tumor markers. Despite atypical features, the excellent prognosis following fertility-sparing resection underscores the significance of conservative treatment in young females.ConclusionThis case highlights the occurrence of a large mature cystic teratoma with elevated CA-19-9 in a pediatric patient with no complications such as torsion, rupture, or malignancy. The elevation in CA-19-9 likely relates directly to the teratoma itself. A conservative, fertility-sparing surgical approach proved effective, emphasizing the importance of careful preoperative evaluation and management in similar cases.